Table 1.
Maternal and Infant Characteristics
| Median (range) or no. (%) | HIV+ N=16 | Controls N=24 |
|---|---|---|
| Maternal age, years | 26 (19–40) | 27 (20–38) |
| Maternal race/ethnicity | ||
| Black, non-Hispanic | 11 (69%) | 15 (62%) |
| White, non-Hispanic | 3 (19%) | 8 (33%) |
| White, Hispanic | 2 (12%) | 1 (5%) |
| Maternal prepregnancy BMI, g/m2a | 39.8 (29.4–53.5) | 31.5 (20.0–46.6) |
| Delivery during high-sun monthb | 8 (50%) | 19 (79%) |
| Gestational age of infant, weeksa | 38 (35–40) | 39 (36–40) |
| Delivery by Cesarean section | 12 (75%) | 12 (50%) |
| Infant weight, kg | 3.1 (2.6–3.9) | 3.3 (2.6–4.1) |
| Time since HIV diagnosis, years | 2.0 (0.3–21.2) | — |
| CD4 count, cells/mm3 | 483 (128–1716) | — |
| Nadir CD4 count, cells/mm3 | 345 (1–814) | — |
| HIV-1 RNA<1,000 copies/ml | 13 (81%) | — |
| ART-naive prior to pregnancy | 9 (56%) | — |
| Gestational NRTI use, months | 5.5 (0–9) | — |
| Gestational PI use, months | 4.5 (0–9) | — |
| Gestational NNRTI use, months | 0 (0–0) | — |
a
p<0.05.
b
Defined as April 1–September 30.
BMI, body mass index; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitors.